ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION
Provided is a method of treating benign prostatic hyperplasia (BPH) in a patient. Also provided is a method of inhibiting non-adrenergic contraction of a smooth muscle. Additionally provided is a method of inhibiting proliferation of human prostate cells.
1 . A method of treating benign prostatic hyperplasia (BPH) in a patient, the method comprising treating the patient with (a) onvansertib and (b) an α1-blocker, a 5-α-reductase inhibitor, a phosphodiesterase-5 enzyme inhibitor, or a combination thereof.
2 . The method of claim 1 , wherein the patient is treated with onvansertib and an α1-blocker.
3 . The method of claim 1 , wherein the method reduces symptom of BPH or improves urinary flow (Qmax) by greater than 50%.
4 . The method of claim 2 , wherein the α1-blocker is alfuzosin, doxazosin, tamsulosin or silodosin.
5 . A method of inhibiting non-adrenergic contraction of a smooth muscle, the method comprising treating the smooth muscle with onvansertib.
6 . The method of claim 5 , wherein the smooth muscle contraction is endothelin-1 induced or ATP induced (purinergic).
7 . The method of claim 5 , wherein the smooth muscle is prostate tissue.
8 . The method of claim 7 , wherein the prostate tissue is human prostate tissue.
9 . The method of claim 7 , wherein the prostate tissue is in a patient with benign prostatic hyperplasia (BPH).
10 . A method of inhibiting proliferation of prostate cells, the method comprising treating the human prostate cells with onvansertib in a manner sufficient to inhibit proliferation of the prostate cells.
11 . The method of claim 10 , wherein the human prostate cells or tissue are in a patient with BPH.